SECsense Logo

Agios Pharmaceuticals 8-K Report: Key Updates & Insights (Jan 2025)

$AGIO
Form 8-K
Filed on: 2025-01-13
Source
Agios Pharmaceuticals 8-K Report: Key Updates & Insights (Jan 2025)

Here are the key pieces of information extracted from the provided section of the financial report:

  1. Company Information:
  • Name: Agios Pharmaceuticals, Inc.
  • CIK Number: 0001439222
  • State of Incorporation: Delaware (DE)
  • Address: 88 Sidney Street, Cambridge, MA 02139
  • Contact Number: (617) 649-8600
  1. SEC Filing Details:
  • Filing Type: 8-K (Current Report)
  • Filing Date: January 13, 2025
  • SEC Central Index Key (CIK): 0001439222
  • File Number: 001-36014
  1. Securities Information:
  • Common Stock: Par value of $0.001 per share
  • Ticker Symbol: AGIO
  • Exchange: NASDAQ
  1. Period Context:
  • Reporting Period: The report covers a specific duration from January 13, 2025, to January 13, 2025.

Insights:

  • The report appears to be a current report (8-K), which is typically filed to announce major events that shareholders should know about. This could indicate that there is significant news or developments regarding Agios Pharmaceuticals.
  • The details confirm Agios Pharmaceuticals' compliance with SEC regulations and provide essential company and contact information for stakeholders.
  • The inclusion of a specific filing date and period context suggests that the information provided in the 8-K is time-sensitive, emphasizing the importance of reviewing the content promptly.

This analysis captures the fundamental aspects of the report that stakeholders, investors, and analysts might focus on for decision-making and further investigation.